- Open Access
Antisense oligonucleotide targeting Livin induces apoptosis of human bladder cancer cell via a mechanism involving caspase 3
© Chuan et al; licensee BioMed Central Ltd. 2010
- Received: 21 April 2010
- Accepted: 3 June 2010
- Published: 3 June 2010
Background and Aim
in recent years, Livin, a new member of IAPs family, is found to be a key molecule in cancers. Researchers consider Livin may become a new target for tumor therapy; however, the role of it in bladder cancer is still unclear. The purpose of this article is to investigate Antisense Oligonucleotide (ASODN) of Livin on treating bladder cancer cell and underlying mechanisms.
Phosphorathioate modifying was used to synthesize antisense oligonucleotides targeting Livin, followed by transfection into human bladder cancer cell 5637. After transfection, Livin mRNA and protein level, cell proliferation and apoptosis changes, caspase3 level and its effect on human bladder cancer transplantable tumor in nude mice were measured.
results showed Livin ASODN effectively inhibited Livin expression and tumor cell proliferation, and these effects probably through enhanced caspase3 activity and apoptosis of tumor cells. In nude mice transplantable tumor model, Livin expressions were inhibited meanwhile caspase3 expression was increased. Tumor growth slowed down and apoptosis was enhanced.
Our data suggest that Livin plays an important role in inhibiting apoptosis of bladder cancer cells. Livin ASODN may promote cell apoptosis, inhibit bladder cancer growth, and become one of the methods of gene therapy for bladder cancer.
- Bladder Cancer
- Antisense Oligonucleotide
- Bladder Cancer Cell
- Bladder Cancer Cell Line
- Human Bladder Cancer Cell
Inhibition of apoptosis is one of the important mechanisms for the growth of many malignant tumor cells. IAPs, the new anti-apoptotic protein families which independent of Bcl-2, are a hot apoptosis research field in recent years, and can play an important role in inhibiting tumor cell growth. Until now, 8 members of IAPs family were found: NAIP, ILP-2, c-IAPl(MIHB, HIAP-2), c-IAP2((HIAP-1, MIHC, API2), XIAP(hILP, MIHA, ILP-1), Bruce(apollon), survivin and Livin(ML-IAP, KIAP). Livin as a new member of IAPs family was found in recent years, which shows high expression level in some specific tumor tissue cells, but little, if not none, in normal tissues. Researchers had found that it may become the target for tumor therapy [8, 9]. In 2003, Gazzaniga et al  used RT-PCR in 30 cases of transitional cell carcinoma of the bladder (TCCB) tumor tissue to detect Livin mRNA expression level, and the results showed that normal bladder tissues did not express Livin, while TCCB tissues expressed high level of Livin. They made a follow-up visit for 4 years to these patients and finally discovered that the Livin positive expression was quite related to the tumor recrudescence. So the objective of this study is to apply antisense oligonucleotide for Livin gene to investigate the effect of inhibition Livin expression on proliferation and apoptosis of human bladder cancer cell 5637 in vivo and in vitro, and to further explore the mechanisms under the phenomenon, and to provide a theoretical basis for treatment of bladder cancer using antisense oligonucleotide with Livin as a target gene.
Synthesis of antisense oligonucleotide
Livin antisense oligonucleotide sequence was from the literature , and a misantisense oligonucleotides (MSODN) was also designed. According to Genbank, ASODN and MSODN do not match with any known mammalian gene. They were synthesized by Takara Biotechnology Co., Ltd (Dalian, China) with phosphorathioate oligonucleotide technology followed by PAGE purification. Using serum-free and antibiotic-free RPMI1640 medium to dilute the stock solution to 20 μmo1/L followed by filtration of microporous filtering film and preservation at -20°C. Antisense sequence: 5'-ACCATCACCGGCTGCCCAGT-3', target sequence: 5'-ACUGGGCAGCCGGUGAUGGU-3', missense sequence: 5'-GTCAGGATCTTCCCACGGAG-3'.
Culture and transfection of human bladder cancer cell line 5637
Human TCCB cell line 5637 was purchased from the Institute of Cell Research, Shanghai, and Chinese Academy of Sciences. The cells were cultured in RPMI 1640 medium (Gibico, U.S.A.) supplemented with 10% fetal bovine serum (FBS, Sijixin Inc., China) and 1% penicillin-streptomycin (Invitrogen, U.S.A.). All cells were cultured in 6-well plate at 37°C with 5% CO2. During the logarithmic growth phase, the liposome was respectively mixed with antisense and missense oligonucleotides in serum-free medium (Invitrogen, USA) in accordance with Lipofectamine™ 2000 (Invitrogen, USA) instructions to form liposome-oligonucleotide complexes, which were then added into culture plate. The final concentration of oligonucleotide was 160 nmolL-1. Seventy-two hours after transfection, cells were harvested for RT-PCR, Western Blot, cell immunofluorescence, flow cytometry analysis, transmission electron microscope observation and Caspase3 activity measurement.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-dimethyl tetrazolium bromide (MTT) assay for cell inhibition
Cells in logarithmic growth phase were seeded in 96-well plates at 5 × 104 cells per well. Then cells were transfected with antisense oligonucleotide of different concentrations (the final concentrations are 0 nmol/L, 20 nmol/L, 40 nmol/L, 60 nmol/L, 80 nmol/L, 100 nmol/L, 120 nmol/L, 140 nmol/L, 160 nmol/L, 180 nmol/L, 200 nmol/L) for 6 hr, followed by culturing with nomal medium for 66 hr. Four hours before stop culturing, 20 μL of 5 mg/mL MTT (sigma, U.S.A.) was added to the culture medium. After incubation, the culture medium was removed and 200 μL of dimethylsulphoxide(DMSO) was added to resolve the crystal. Absorbance was measured at 490 nm. Each sample was assayed for four times. Tumor cell inhibition rate = (1 - treated group absorbance/control group absorbance) × 100%.
Total RNA was extracted from tissue homogenates or cell lysates with TRIzol reagent (invitrogen, U.S.A.) and RT-PCR was carried out with a RNA PCR Kit Ver.3.0 (TaKaRa, Japan) according to the kit's instructions. Livin-specific primers discriminating between the α- and the β-variant were: forward, 5'-GTCCCTGCCTCTGGGTAC-3'; reverse, 5'-CAGGGAGCCCACTCTGCA-3'. Product sizes 368 and 314 bp, respectively. The primers used for GAPDH were: forward, Sense: 5'-ATGACATCAAGAAGGTGGTG-3'; reverse, 5'-CATACCAGGAAATGAGCTTG-3', which yields a product of 177 bp. The PCR condition was: 95°C for 2 min, then 38 cycles at 94°C for 30 seconds, 64°C for 45 seconds, and 72°C for 30 seconds in 1.5 mM MgCl2-containing reaction buffer. Five μL of RT-PCR products were resolved on 1.5% agarose gels. The gels were stained with ethidium bromide (EB) and were scanned for densitometric estimation of the Livin products with GAPDH products serving as the internal control.
Western Blot Analysis
Proteins were extracted from cell lines as previous described: Proteins were separated by 12% SDS polyacrylamide gel electrophoresis, transferred to an nitrocellulose membrane (Millipore, USA), and detected with a monoclonal anti-β-actin antibody (R&D systems, USA) or polyclonal anti-Livin antibody (R&D systems, USA), employing enhanced chemiluminescence (PIERCE, USA).
Immunofluorescence, immunohistochemical and laser confocal microscope for expression of Livin
Cells were transfected with different reagents 72 hours and then disposed the culture medium. Use 0.01 mol/L PBS to rinse, and 4% paraformaldehyde to fix at room temperature followed by reaction with 0.4% Triton-X100 at room temperature for 20 min. Add rabbit serum followed by reaction for 30 min at room temperature. Add primary antibody (goat anti-human Livin, R&D systems, USA) and place it in a wet box for overnight at 4°C followed by 0.01 mol/L PBS rinse. Add secondary antibody labeled with FITC (rabbit anti-goat) and set it in a wet box at room temperature for 1 h followed by 0.01 mol/L PBS rinse and 50% glycerol mounting. Use laser scanning confocal microscope (Leica Tcs Sp2) for observation and imaging.
For immunohistochemical examination, tumor tissue samples were fixed with 4% paraformaldehyde for 72 hr, dehydrated in graded ethanol, and embedded in paraffin followed by serial sections. SP kit, goat anti-human Livin antibody, rabbit anti-human Caspase3 antibodies were purchased from the American R&D systems. Immunohistochemistry staining: repair the antigen with trypsin, add goat anti-human Livin antibodies or rabbit anti-human Caspase3 antibody followed by PBS washing, DAB color development
Transmission electron microscope for cell morphology
After transfection, the cells in each group were centrifuged at 1500 rpm for 20 min, followed by fixing with 4% paraformaldehyde for 1 hr, and then transferring into pre-chilled 1% glutaraldehyde. The samples were dehydrated in graded ethanol, embedded in epon 812, and then cut into ultrathin or semithin sections. The sections were stained and examined under a Hitachi H-600 transmission electron microscope.
Detection of apoptotic cells by flowcytometry
Cells were collected by low speed centrifugation and washed with ice-cold PBS then recollected by centrifugation. After washing with PBS twice the cells were incubated in 10 μl Annexin V-FITC (fluorescein isothiocyanate) and 5 μl propidium iodine (PI) at 4°C for 30 minutes using the Annexin V-FITC apoptosis assay kit (KeyGen Biotech. Co. Ltd. Nanjing, China). Finally, the cells were analyzed within 60 minutes by flow cytometry.
Determination of Caspase3 activities by kinase assay
The experiments conformed to the operating instructions provided by the kit (BioVision Inc.): cells were collected and added with cell lysis solution followed by incubation on ice for 10 min and centrifugation. The supernatant was added with reaction buffer and coupling substrate followed by 37°C water bath for 1 h. The absorbance values were determined by enzyme-linked assay at 405 nm wavelength. The values were regarded as the relative activity of Caspase3.
Nude mouse xenograft model
Female BALB/c nude mice, 4 weeks of age, weighting 16 ± 0.6 g, were purchased from Experimental Animal Center of Chinese Academy of Sciences, Shanghai, China. Mice were housed in microisolator cages in a specific pathogen-free (SPF) condition with 12-hr light-dark cycles. Mice were subcutaneously implanted with 1 × 107 5637 cells. Once tumors reached approximately 60 μL in volume, the mice were allocated to receive either ASODN or MSODN treatment, with the concentration of 200 nmol/L and 0.2 ml/mice. The nude mice injected with ASODN were termed as treatment group and the nude mice injected with MSODN were termed as control group. Complexes of ASODN or MSODN plus 4 μL invivo-jetPEI™ (polyplus-transfection Inc., U.S.A.) and also plus 160 μL 5% glucose were directly injected into the tumor once every other day with a total of 7 times. Tumor dimensions were measured once every three days and the tumor volumes calculated using the formula: 1/2 × a × b2, where a and b respectively represented the larger and smaller tumor diameter. At the end of the treatment, mice were killed by overdose of ketamine (400 mg/kg) and xylazine (50 mg/kg) and necropsy was performed. Tumor tissue samples were prepared for Immunohistochemistry or TUNEL cell apoptosis detection. Tumor growth inhibition (TGI) was calculated using the formula TGI (%) = (1-MT/MC) × 100, where MT and MC are the mean tumor masses in the treatment group and control group respectively.
TUNEL analyses for cell apoptosis detection
For detection of apoptosis, TUNEL analyses were performed using the in situ cell death detection kit (Roche Molecular Biochemicals, USA). Operations were carried out according to kit instructions. 10 high-powerfields were selected for each case. Count the number of apoptotic cells and total number of cells for each powerfield to calculate the percentage of apoptotic cells (number of apoptotic cells in each powerfield/total cell number in each powerfield) i.e., apoptosis index (AI).
The results were expressed as mean ± standard deviation. One-way analysis of variance (ANOVA) was used to determine the levels of difference between all groups. Comparisons for all pairs were made using Student-Newman-Keuls (SNK) test. p < 0.05 was considered statistically significant.
Livin antisense oligonucleotide dose-dependently inhibit bladder cancer cell growth
Livin mRNA and protein expression was inhibited after Livin ASODN transfection
Then we performed Western blot to evaluate Livin protein expression. Confirmed with the results of RT-PCR, the expression of Livinα and Livinβ in the antisense group was significantly lower than the ones in missense group, liposome group and PBS group, while the expression of Livinα and Livinβ in the last three groups were similar (Fig. 2b).
Cell morphology changed and apoptosis rate increased after transfection with Livin ASODN
Cellular caspase3 activities were increased after transfection with Livin ASODN
Livin ASODN transfection inhibited 5637 tumor growth in vivo
Cell apoptosis was induced after transfected with Livin ASODN in vivo
Randomly select 10 high power fields for each case to calculate the apoptotic index (AI). The antisense group apoptotic index was 19.60 ± 5.91, which was significantly higher than the control group (3.48 ± 2.35), and the difference was significant with P < 0.05.
Livin expression was inhibited meanwhile Caspas 3 expression was increased after transfection with Livin ASODN
Caspas 3 immunohistochemical staining showed that the majority of tumor cells in the tumor tissues of ASODN injection group were stained dark brown, while the tumor cell caspas 3 staining of MSODN injection group was relatively light, and the number of stained cells was relatively small (Fig. 9c, d).
In recent years, using EST clone containing the BIR sequences, Vucic D, Kasof GM, etc. found Livin--a new member of this gene family in human fetal kidney cDNA library according to the IAPs homologous sequences [12, 13]. Livin produces two kinds of mRNA isomers in the transcription process due to the different ways of splicing. They have 1351 and 1297 base pairs, respectively. In spite of the 54 bp difference in length, properties of these two different mRNAs are exactly the same. The proteins coded by them were 298 and 280 amino acids with the molecular weight of about 33 kD and 30 kD, and were respectively termed as Livin α and Livin β . For normal adults, most tissues do not express Livin at all (except placenta), but in some cancer cell lines such as melanoma cell lines (G361 and SK-Mel29), lymphoma, HaCat cells, and MCF7 breast cancer cells , Livin is highly expressed. In spite of that, Livin was also highly expressed in a number of tumor tissues, such as bladder cancer , lymphoma , lung cancer , hepatocellular carcinoma, and renal carcinoma[17, 18]. Gazzaniga et al screened the apoptosis-related genes in bladder transitional cell carcinoma tumor tissues, including Livin, Survivin, BCL-X and BCL-2/BAX and so on, and then performed a four-year follow-up visit. Results showed that only Livin was related to bladder cancer recurrence in these genes. The tumor average recurrence time of the patients with positive Livin expression after surgery (3.5 months) was much less than the one of the patients with negative Livin expression (27.2 months). The significant differences of recurrence intervals indicated that Livin expression is a sign of poor prognosis of early superficial bladder cancer and it can be used as indicators for monitoring recurrence of bladder cancer. As one of the most common malignant tumors in urinary surgery, the bladder cancer has the most remarkable characteristics of easily postoperative recurrence. Therefore, Livin as a target gene for treating bladder cancer has a good application prospect.
Antisense nucleic acid is a naturally existing or synthetic nucleotide sequence. Livin ASODN hybridizes with target genes through Watson Crick principle of complementary base pairing to prevent gene expression, inhibit cell proliferation, promote apoptosis, and achieve the purpose of preventing or treating tumors. The natural oligonucleotide is easily degraded, but phosphorathioate modifying can increase the capacity of its tolerance to nucleic acid hydrolysis, with good solubility and hybridization properties. The effectiveness and safety have been universally accepted by researchers. Currently the antisense oligonucleotide with bcl-2 as the target gene (trade name: Oblimersen) is in Phase III clinical trials with the permit of FDA (mainly treat malignant melanoma, chronic lymphocytic leukemia, multiple myeloma, etc.) . The drug achieves the purpose of cancer treatment by inhibiting the expression of bcl-2 inside the tumor cells and inducing the tumor cell apoptosis. There are also a variety of antisense oligonucleotides anticancer drugs in clinical trials [20, 21]. In the present study, phosphorathioate modifying greatly enhanced the anti-ribozyme decomposition capacity of Livin ASODN. The supplement of cationic liposome transfection further increased its stability and improved the ability of uptake by cells. Using RT-PCR, Western blot, immunocytochemistry, immunohistochemistry, we found that Livin ASODN could inhibit the expression of Livin mRNA and protein. We further observed that the cell growth was inhibited and the apoptosis increased from MTT, flow cytometry, TUNEL method and morphological observations.
Caspases protein plays an important role in apoptosis. Most of the stimuli induce apoptosis through the Caspase protein cascade activation reactions. Caspases protein family has more than 10 members. Literatures have reported that Livin can interact with Caspase-3, -6, -7, -8, -9, -10  (especially Caspase 3) to inhibit the process of apoptosis. Using immunohistochemistry, we observed that after the injection of Livin ASODN, the expression of Caspase 3 in tumor tissues increased, which was probably because Livin ASODN inhibited the expression of Livin and then removed the binding inhibition to Caspase 3. Besides, Caspase 3 removal function also enhanced, which lead to increased cell apoptosis.
In conclusion, Livin ASODN could specifically inhibit the expression of Livin in human bladder cancer cell 5637 and induce apoptosis of bladder cancer cells. It may be a potential and most promising strategy for bladder cancer.
This study was supported by research grant from Research Development Foundation of Health Bureau of ChongQing (No. 04-2-131).
- Roy N, Mahadevan MS, McLean M: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell. 1995, 80 (1): 167-178. 10.1016/0092-8674(95)90461-1.View ArticleGoogle Scholar
- Richter BW, Mir SS, Eiben LJ: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol. 2001, 21 (13): 4292-4301. 10.1128/MCB.21.13.4292-4301.2001.View ArticleGoogle Scholar
- Rothe M, Pan MG, Henzel WJ: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995, 83 (7): 1243-1252. 10.1016/0092-8674(95)90149-3.View ArticleGoogle Scholar
- Liston P, Roy N, Tamai K: Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996, 379 (6563): 349-353. 10.1038/379349a0.View ArticleGoogle Scholar
- Chen Z, Naito M, Hori S: A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1996, 264 (3): 847-854. 10.1006/bbrc.1999.1585.View ArticleGoogle Scholar
- Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3 (8): 917-921. 10.1038/nm0897-917.View ArticleGoogle Scholar
- Salvesen GS, Duckett CS: IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002, 3 (6): 401-410. 10.1038/nrm830.View ArticleGoogle Scholar
- Chang Hong, Shimmer Aaron: Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther. 2007, 6 (1): 24-30. 10.1158/1535-7163.MCT-06-0443.View ArticleGoogle Scholar
- Liu B, Han M, Wen JK, Wang L: Livin/ML-IAP as a new target for cancer treatment. Cancer Lett. 2007, 250 (2): 168-176. 10.1016/j.canlet.2006.09.024.View ArticleGoogle Scholar
- Gazzaniga P, Gradilone A, Giuliani L: Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis-related genes in the Progression of superficial bladder cancer. Ann Oncol. 2003, 14 (1): 85-89. 10.1093/annonc/mdg002.View ArticleGoogle Scholar
- Huadong Zhang, Shoujun Yuan, Huipeng Chen: Induction effects of antisense phosphorothioate oligodeoxynucleotide of livin mRNA on apoptosis in MCF-7 cells. Chin J Clin Pharmacol Ther. 2004, 9 (12): 1353-1356.Google Scholar
- Vucic D, Stennicke HR, Pisabarro MT: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol. 2000, 10 (21): 1359-1366. 10.1016/S0960-9822(00)00781-8.View ArticleGoogle Scholar
- Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem. 2001, 276 (5): 3238-3246. 10.1074/jbc.M003670200.View ArticleGoogle Scholar
- Ashhab Y, Alian A, Polliack A: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett. 2001, 495 (1-2): 56-60. 10.1016/S0014-5793(01)02366-3.View ArticleGoogle Scholar
- Hariu H, Hirohashi Y, Torigoe T: Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res. 2005, 11 (3): 1000-1009.Google Scholar
- Augello C, Caruso L, Maggioni M: Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. BMC Cancer. 2009, 9 (125): 1471-2407.Google Scholar
- Kempkensteffen C, Hinz S, Christoph F: Expression of the apoptosis inhibitor Livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol. 2007, 28 (3): 132-138. 10.1159/000103008.View ArticleGoogle Scholar
- Crnković-Mertens I, Wagener N, Semzow J: Targeted inhibition of Livin resensitizes renal cancer cells towards apoptosis. Cell Mol Life Sci. 2007, 64 (9): 1137-1144. 10.1007/s00018-007-6510-7.View ArticleGoogle Scholar
- Adis International Limited: Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139 GC 3139, oblimersen sodium. Drugs R D. 2007, 8 (5): 321-334. 10.2165/00126839-200708050-00006.View ArticleGoogle Scholar
- Geary RS, Bradley JD, Watanabe T: Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006, 45 (8): 789-801. 10.2165/00003088-200645080-00003.View ArticleGoogle Scholar
- Chi KN, Eisenhauer E, Fazli L: A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005, 97 (17): 1287-1296. 10.1093/jnci/dji252.View ArticleGoogle Scholar
- Vucic D, Franklin MC, Wallweber HJ: Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J. 2005, 385 (Pt 1): 11-20.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.